Browse recruiting and upcoming clinical trials for Erdheim-Chester disease.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults (≥18) with BRAF V600 mutation–positive cancers, for example melanoma, thyroid, ovarian, colorectal, lung, glioma, multiple myeloma, haematological malignancies and other solid tumours.
What is being studied AIEvaluates vemurafenib plus cobimetinib in adults with BRAF V600 mutation-positive cancers.
Who can join AIPeople with Langerhans cell histiocytosis (LCH) or other histiocytic disorders (for example: LCH‑ND, Erdheim‑Chester, Rosai‑Dorfman).
What is being studied AITests cobimetinib (a MEK‑blocking drug) in people with histiocytic disorders (newly diagnosed in some groups, or relapsed/refractory).
Who can join AIAdults (≥18) with certain Non‑Hodgkin lymphomas, multiple myeloma or plasma‑cell disorders (MGUS/SMM/MM), histiocytic neoplasms, or select solid tumors.
What is being studied AIUses [68Ga]-Pentixafor PET/CT to image CXCR4 expression in hematologic and some solid tumors.
Who can join AIChildren (1 day–18 years) with non-inflammatory arthropathy, including Mucopolysaccharidoses, PPRD, Farber disease, OI, Infantile Systemic Hyalinosis, and Idiopathic Multicentric Osteolysis.
What is being studied AICollects clinical, lab and imaging data to identify causes of non-inflammatory arthropathy in children.
Who can join AIPeople of any age diagnosed with a rare histiocytic disorder (for example ECD, RDD, XG family, MHN, ALK‑positive, mixed histiocytosis, MRH, NX).
What is being studied AICollects clinical, treatment, and outcome data for people with rare histiocytic disorders.